William John McKenna

List of Publications by Year
in descending order

480	74,769	384 134	567 263
papers	citations	h-index	g-index

520	520	520	29226
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	1.0	3,469
2	Effects of Multisite Biventricular Pacing in Patients with Heart Failure and Intraventricular Conduction Delay. New England Journal of Medicine, 2001, 344, 873-880.	13.9	2,560
3	Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2013, 34, 2636-2648.	1.0	2,436
4	Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. European Heart Journal, 2007, 29, 270-276.	1.0	2,280
5	Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Circulation, 2010, 121, 1533-1541.	1.6	1,839
6	American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2003, 42, 1687-1713.	1.2	1,444
7	A molecular basis for familial hypertrophic cardiomyopathy: A Î² cardiac myosin heavy chain gene missense mutation. Cell, 1990, 62, 999-1006.	13.5	1,291
8	Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet, The, 2000, 355, 2119-2124.	6.3	1,270
9	Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: Proposed Modification of the Task Force Criteria. European Heart Journal, 2010, 31, 806-814.	1.0	1,177
10	Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. European Heart Journal, 2005, 26, 516-524.	1.0	1,037
11	HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies. Heart Rhythm, 2011, 8, 1308-1339.	0.3	995
12	Î±-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere. Cell, 1994, 77, 701-712.	13.5	994
13	The Management of Hypertrophic Cardiomyopathy. New England Journal of Medicine, 1997, 336, 775-785.	13.9	945
14	Mutations in the Genes for Cardiac Troponin T and Î±-Tropomyosin in Hypertrophic Cardiomyopathy. New England Journal of Medicine, 1995, 332, 1058-1065.	13.9	887
15	Spectrum of Clinicopathologic Manifestations of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: A Multicenter Study. Journal of the American College of Cardiology, 1997, 30, 1512-1520.	1.2	884
16	The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial. Circulation, 2008, 117, 1189-1200.	1.6	878
17	Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. Journal of the American College of Cardiology, 2000, 36, 2212-2218.	1.2	863
18	Recommendations for competitive sports participation in athletes with cardiovascular disease: A consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. European Heart Journal, 2005, 26, 1422-1445.	1.0	860

#	Article	IF	Citations
19	Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. Journal of the American College of Cardiology, 2002, 40, 111-118.	1.2	855
20	A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.0	848
21	Recommendations for interpretation of 12-lead electrocardiogram in the athlete. European Heart Journal, 2010, 31, 243-259.	1.0	730
22	Prognostic Significance of Myocardial Fibrosis in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2010, 56, 867-874.	1.2	720
23	The Cardiac Mechanical Stretch Sensor Machinery Involves a Z Disc Complex that Is Defective in a Subset of Human Dilated Cardiomyopathy. Cell, 2002, 111, 943-955.	13.5	712
24	Toward clinical risk assessment inhypertrophic cardiomyopathy withgadolinium cardiovascular magnetic resonance. Journal of the American College of Cardiology, 2003, 41, 1561-1567.	1.2	707
25	Mutations in the Gene for Cardiac Myosin-Binding Protein C and Late-Onset Familial Hypertrophic Cardiomyopathy. New England Journal of Medicine, 1998, 338, 1248-1257.	13.9	701
26	HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace, 2011, 13, 1077-1109.	0.7	699
27	Characteristics and Prognostic Implications of Myosin Missense Mutations in Familial Hypertrophic Cardiomyopathy. New England Journal of Medicine, 1992, 326, 1108-1114.	13.9	687
28	A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). American Heart Journal, 1997, 134, 44-54.	1.2	648
29	Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and hemodynamic features. American Journal of Cardiology, 1981, 47, 532-538.	0.7	611
30	Left-Dominant Arrhythmogenic Cardiomyopathy. Journal of the American College of Cardiology, 2008, 52, 2175-2187.	1.2	590
31	Hypertrophic cardiomyopathy. Lancet, The, 2004, 363, 1881-1891.	6.3	558
32	Mutations in the cardiac myosin binding proteinâ€“C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nature Genetics, 1995, 11, 434-437.	9.4	540
33	Mapping a Gene for Familial Hypertrophic Cardiomyopathy to Chromosome 14q1. New England Journal of Medicine, 1989, 321, 1372-1378.	13.9	511
34	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm, 2019, 16, e301-e372.	0.3	494
35	Clinical and Genetic Characterization of Families With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Provides Novel Insights Into Patterns of Disease Expression. Circulation, 2007, 115, 1710-1720.	1.6	491
36	Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2003, 42, 873-879.	1.2	484

#	Article	IF	Citations
37	Mutations in Cypher/ZASPin patients with dilated cardiomyopathy and left ventricular non-compaction. Journal of the American College of Cardiology, 2003, 42, 2014-2027.	1.2	479
38	Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST). American Heart Journal, 1999, 138, 78-86.	1.2	462
39	Assessment of Permanent Dual-Chamber Pacing as a Treatment for Drug-Refractory Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. Circulation, 1999, 99, 2927-2933.	1.6	460
40	American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. European Heart Journal, 2003, 24, 1965-1991.	1.0	448
41	Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet, The, 2001, 357, 420-424.	6.3	436
42	Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Is a Fully Penetrant, Lethal Arrhythmic Disorder Caused by a Missense Mutation in the TMEM43 Gene. American Journal of Human Genetics, 2008, 82, 809-821.	2.6	431
43	Natural history and familial characteristics of isolated left ventricular non-compaction. European Heart Journal, 2005, 26, 187-192.	1.0	427
44	A New Diagnostic Test for Arrhythmogenic Right Ventricular Cardiomyopathy. New England Journal of Medicine, 2009, 360, 1075-1084.	13.9	424
45	Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2010, 31, 2715-2726.	1.0	408
46	Expression of Inducible Nitric Oxide Synthase in Human Heart Failure. Circulation, 1996, 93, 1087-1094.	1.6	402
47	Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease Evidence for a disease specific abnormality of the myocardial interstitium. European Heart Journal, 2003, 24, 2151-2155.	1.0	397
48	Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. Journal of Clinical Investigation, 2002, 109, 357-362.	3.9	389
49	Sudden arrhythmic death syndrome: familial evaluation identifies inheritable heart disease in the majority of families. European Heart Journal, 2008, 29, 1670-1680.	1.0	372
50	Diagnosis of left-ventricular non-compaction in patients with left-ventricular systolic dysfunction: time for a reappraisal of diagnostic criteria?. European Heart Journal, 2007, 29, 89-95.	1.0	370
51	Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. Journal of the American College of Cardiology, 2003, 41, 1776-1782.	1.2	359
52	Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Circulation, 2015, 132, 441-453.	1.6	356
53	Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. European Heart Journal, 2006, 27, 1933-1941.	1.0	352
54	Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Associated with Mutations in the Desmosomal Gene Desmocollin-2. American Journal of Human Genetics, 2006, 79, 978-984.	2.6	336

#	Article	IF	Citations
55	Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. Journal of Electrocardiology, 2012, 45, 433-442.	0.4	335
56	Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2005, 45, 1251-1258.	1.2	323
57	Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: A two-dimensional echocardiographic study. Journal of the American College of Cardiology, 1983, 2, 437-444.	1.2	311
58	Sarcomere Protein Gene Mutations in Hypertrophic Cardiomyopathy of the Elderly. Circulation, 2002, 105, 446-451.	1.6	311
59	Remodeling of myocyte gap junctions in arrhythmogenic right ventricular cardiomyopathy due to a deletion in plakoglobin (Naxos disease). Heart Rhythm, 2004, 1, 3-11.	0.3	309
60	Familial dilated cardiomyopathy. Journal of the American College of Cardiology, 1999, 34, 181-190.	1.2	304
61	Association of Angiotensin-Converting Enzyme GeneI/DPolymorphism With Change in Left Ventricular Mass in Response to Physical Training. Circulation, 1997, 96, 741-747.	1.6	296
62	Genetic and Molecular Basis of Cardiac Arrhythmias: Impact on Clinical Management Parts I and II. Circulation, 1999, 99, 518-528.	1.6	295
63	Classification, Epidemiology, and Global Burden of Cardiomyopathies. Circulation Research, 2017, 121, 722-730.	2.0	291
64	Physiologic limits of left ventricular hypertrophy in elite junior athletes. Journal of the American College of Cardiology, 2002, 40, 1431-1436.	1.2	289
65	Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. Journal of the American College of Cardiology, 2002, 40, 1445-1450.	1.2	285
66	Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. International Journal of Cardiology, 2020, 319, 106-114.	0.8	283
67	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. Journal of Clinical Investigation, 2003, 111, 209-216.	3.9	278
68	Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart, 2012, 98, 1436-1441.	1.2	276
69	Hypertrophic Cardiomyopathy. Circulation, 2001, 104, 1380-1384.	1.6	274
70	Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circulation, 2000, 101, E101-6.	1.6	272
71	Prophylactic Implantable Defibrillator in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia and No Prior Ventricular Fibrillation or Sustained Ventricular Tachycardia. Circulation, 2010, 122, 1144-1152.	1.6	272
72	Atrial fibrillation in hypertrophie cardiomyopathy: A longitudinal study. Journal of the American College of Cardiology, 1990, 15, 1279-1285.	1.2	271

#	Article	IF	Citations
73	Metabolic Modulator Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic Cardiomyopathy. Circulation, 2010, 122, 1562-1569.	1.6	267
74	Novel Mutation in Desmoplakin Causes Arrhythmogenic Left Ventricular Cardiomyopathy. Circulation, 2005, 112, 636-642.	1.6	266
75	Prospective Prognostic Assessment of Blood Pressure Response During Exercise in Patients With Hypertrophic Cardiomyopathy. Circulation, 1997, 96, 2987-2991.	1.6	263
76	Comparison of Electrocardiographic Criteria for the Detection of Cardiac Abnormalities in Elite Black and White Athletes. Circulation, 2014, 129, 1637-1649.	1.6	261
77	The Cardiac Desmosome and Arrhythmogenic Cardiomyopathies. Circulation Research, 2010, 107, 700-714.	2.0	260
78	Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. American Journal of Cardiology, 2001, 88, 275-279.	0.7	254
79	Familial Dilated Cardiomyopathy: Cardiac Abnormalities Are Common in Asymptomatic Relatives and May Represent Early Disease. Journal of the American College of Cardiology, 1998, 31, 195-201.	1.2	249
80	Mutations in the muscle LIM protein and Î±-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. Molecular Genetics and Metabolism, 2003, 80, 207-215.	0.5	249
81	Genetic variation in SCN10A influences cardiac conduction. Nature Genetics, 2010, 42, 149-152.	9.4	248
82	Gender Differences in Survival in Advanced Heart Failure. Circulation, 1999, 99, 1816-1821.	1.6	240
83	Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. European Heart Journal, 2020, 41, 1414-1429.	1.0	239
84	Arrhythmogenic Cardiomyopathy: Etiology, Diagnosis, and Treatment. Annual Review of Medicine, 2010, 61, 233-253.	5.0	238
85	Gene for Arrhythmogenic Right Ventricular Cardiomyopathy With Diffuse Nonepidermolytic Palmoplantar Keratoderma and Woolly Hair (Naxos Disease) Maps to 17q21. Circulation, 1998, 97, 2049-2058.	1.6	232
86	Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. Journal of Clinical Investigation, 2002, 109, 357-362.	3.9	228
87	Familial Evaluation in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation, 2011, 123, 2701-2709.	1.6	226
88	Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 1999, 33, 1596-1601.	1.2	221
89	Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. European Journal of Heart Failure, 2002, 4, 411-417.	2.9	221
90	Mutations in the Lamin A/C gene mimic arrhythmogenic right ventricular cardiomyopathy. European Heart Journal, 2012, 33, 1128-1136.	1.0	220

#	Article	IF	Citations
91	Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. Journal of the American College of Cardiology, 2004, 44, 2033-2040.	1.2	216
92	Cardiovascular Magnetic Resonance in Arrhythmogenic Right Ventricular Cardiomyopathy Revisited. Journal of the American College of Cardiology, 2006, 48, 2132-2140.	1.2	214
93	Evidence From Human Myectomy Samples That MYBPC3 Mutations Cause Hypertrophic Cardiomyopathy Through Haploinsufficiency. Circulation Research, 2009, 105, 219-222.	2.0	210
94	A Novel Dominant Mutation in Plakoglobin Causes Arrhythmogenic Right Ventricular Cardiomyopathy. American Journal of Human Genetics, 2007, 81, 964-973.	2.6	208
95	Role of Genetic Analysis in the Management of Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Journal of the American College of Cardiology, 2007, 50, 1813-1821.	1.2	207
96	Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 1988, 11, 147-153.	1.2	206
97	Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. Journal of Medical Genetics, 2013, 50, 228-239.	1.5	203
98	A disease locus for familial hypertrophic cardiomyopathy maps to chromosome 1q3. Nature Genetics, 1993, 3, 333-337.	9.4	197
99	Clinical Expression of Plakophilin-2 Mutations in Familial Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation, 2006, 113, 356-364.	1.6	193
100	Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. Journal of the American College of Cardiology, 1990, 15, 1527-1534.	1.2	188
101	Genetics of Right Ventricular Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2005, 16, 927-935.	0.8	184
102	Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. British Heart Journal, 2002, 87, 169-176.	2.2	183
103	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. European Journal of Preventive Cardiology, 2017, 24, 41-69.	0.8	181
104	Cardiologic abnormalities in Noonan syndrome: Phenotypic diagnosis and echocardiographic assessment of 118 patients. Journal of the American College of Cardiology, 1993, 22, 1189-1192.	1.2	180
105	Prevalence of Sarcomere Protein Gene Mutations in Preadolescent Children With Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 2009, 2, 436-441.	5.1	176
106	Preclinical Diagnosis of Familial Hypertrophic Cardiomyopathy by Genetic Analysis of Blood Lymphocytes. New England Journal of Medicine, 1991, 325, 1753-1760.	13.9	174
107	Genotype-phenotype assessment in autosomal recessive arrhythmogenic right ventricular cardiomyopathy (Naxos disease) caused by a deletion in plakoglobin. Journal of the American College of Cardiology, 2001, 38, 1477-1484.	1.2	174
108	Prevalence of Hypertrophic Cardiomyopathy in Highly Trained Athletes. Journal of the American College of Cardiology, 2008, 51, 1033-1039.	1.2	171

#	Article	IF	Citations
109	Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. European Heart Journal, 2015, 36, ehv162.	1.0	171
110	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. Journal of Clinical Investigation, 2003, 111, 209-216.	3.9	169
111	Prevalence, Clinical Significance, and Genetic Basis of Hypertrophic Cardiomyopathy With Restrictive Phenotype. Journal of the American College of Cardiology, 2007, 49, 2419-2426.	1.2	167
112	Quantification of left ventricular trabeculae using fractal analysis. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 36.	1.6	167
113	Genetic Risk of Arrhythmic Phenotypes in Patients With Dilated Cardiomyopathy. Journal of the American College of Cardiology, 2019, 74, 1480-1490.	1.2	167
114	Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 158-168.	3.3	165
115	The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). Journal of the American College of Cardiology, 2005, 45, 400-408.	1.2	164
116	Arrhythmia in hypertrophic cardiomyopathy: Exercise and 48 hour ambulatory electrocardiographic assessment with and without beta adrenergic blocking therapy. American Journal of Cardiology, 1980, 45, 1-5.	0.7	163
117	Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy. Lancet, The, 2004, 363, 371-372.	6.3	162
118	Altered Desmosomal Proteins in Granulomatous Myocarditis and Potential Pathogenic Links to Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2011, 4, 743-752.	2.1	161
119	Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. European Heart Journal, 2009, 30, 2599-2605.	1.0	160
120	Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome. Journal of the American College of Cardiology, 2005, 45, 922-930.	1.2	155
121	Electrophysiological abnormalities precede overt structural changes in arrhythmogenic right ventricular cardiomyopathy due to mutations in desmoplakin-A combined murine and human study. European Heart Journal, 2012, 33, 1942-1953.	1.0	155
122	Disease Pathways and Novel Therapeutic Targets in Hypertrophic Cardiomyopathy. Circulation Research, 2011, 109, 86-96.	2.0	153
123	Prevalence and Clinical Significance of Cardiovascular Abnormalities in Patients With the LEOPARD Syndrome. American Journal of Cardiology, 2007, 100, 736-741.	0.7	150
124	Prospective Familial Assessment in Dilated Cardiomyopathy. Circulation, 2007, 115, 76-83.	1.6	148
125	High-Density Substrate Mapping in Brugada Syndrome. Circulation, 2009, 120, 106-117.	1.6	148
126	Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. Journal of the American College of Cardiology, 2000, 36, 864-870.	1.2	146

#	Article	IF	Citations
127	The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart, 2012, 98, 116-125.	1.2	146
128	Genetics of inherited cardiomyopathy. European Heart Journal, 2012, 33, 296-304.	1.0	146
129	Prevalence of Desmosomal Protein Gene Mutations in Patients With Dilated Cardiomyopathy. Circulation: Cardiovascular Genetics, 2010, 3, 314-322.	5.1	145
130	Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart, 2014, 100, 1851-1858.	1.2	144
131	Exercise Capacity in Hypertrophic Cardiomyopathy. Circulation, 1995, 92, 2886-2894.	1.6	143
132	Side effects and possible contraindications of amiodarone use. American Heart Journal, 1983, 106, 916-923.	1.2	141
133	Arrhythmogenic right ventricular cardiomyopathy: Clinical presentation, diagnosis, and management. American Journal of Medicine, 2004, 117, 685-695.	0.6	139
134	Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. American Heart Journal, 1991, 122, 1016-1021.	1.2	136
135	Update of the guidelines on sudden cardiac death of the European Society of Cardiology. European Heart Journal, 2003, 24, 13-15.	1.0	135
136	Desmoglein-2 mutations in arrhythmogenic right ventricular cardiomyopathy: a genotype-phenotype characterization of familial disease. European Heart Journal, 2006, 28, 581-588.	1.0	135
137	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. Heart Rhythm, 2019, 16, e373-e407.	0.3	135
138	Echocardiographic Evaluation in Asymptomatic Relatives of Patients with Dilated Cardiomyopathy Reveals Preclinical Disease. Annals of Internal Medicine, 2005, 143, 108.	2.0	134
139	Dilated Cardiomyopathy Mutations in Three Thin Filament Regulatory Proteins Result in a Common Functional Phenotype. Journal of Biological Chemistry, 2005, 280, 28498-28506.	1.6	133
140	Genetic and Molecular Basis of Cardiac Arrhythmias: Impact on Clinical Management Part III. Circulation, 1999, 99, 674-681.	1.6	131
141	A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart, 2013, 99, 534-541.	1.2	127
142	Cardiac fatigue following prolonged endurance exercise of differing distances. Medicine and Science in Sports and Exercise, 2000, 32, 1067-1072.	0.2	125
143	New insights into the pathology of inherited cardiomyopathy. Heart, 2005, 91, 257-264.	1.2	125
144	Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. American Journal of Cardiology, 2000, 86, 162-168.	0.7	124

#	Article	IF	Citations
145	Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2004, 44, 2315-2325.	1.2	124
146	Novel genotypeâ€“phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. Heart, 2015, 101, 294-301.	1.2	124
147	Comprehensive multi-modality imaging approach in arrhythmogenic cardiomyopathyâ€”an expert consensus document of the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging, 2017, 18, 237-253.	0.5	123
148	Diastolic function in hypertrophic cardiomyopathy: Relation to exercise capacity. Journal of the American College of Cardiology, 1992, 19, 536-540.	1.2	121
149	Cardiac Myosin Binding Protein-C Mutations in Families With Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 2012, 5, 156-166.	5.1	121
150	Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. American Journal of Cardiology, 1984, 54, 802-810.	0.7	117
151	Epidemiology of the inherited cardiomyopathies. Nature Reviews Cardiology, 2021, 18, 22-36.	6.1	117
152	ANKRD1, the Gene Encoding Cardiac Ankyrin Repeat Protein, Is a Novel Dilated Cardiomyopathy Gene. Journal of the American College of Cardiology, 2009, 54, 325-333.	1.2	115
153	A Newly Created Splice Donor Site in Exon 25 of the MyBP-C Gene Is Responsible for Inherited Hypertrophic Cardiomyopathy With Incomplete Disease Penetrance. Circulation, 2000, 101, 1396-1402.	1.6	114
154	Prediction of thromboâ€embolic risk in patients with hypertrophic cardiomyopathy (<scp>HCM</scp>) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.9	114
155	Task force 3: Hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. Journal of the American College of Cardiology, 1994, 24, 880-885.	1.2	113
156	Lamin and the heart. Heart, 2018, 104, 468-479.	1.2	113
157	Update on hypertrophic cardiomyopathy and a guide to the guidelines. Nature Reviews Cardiology, 2016, 13, 651-675.	6.1	110
158	Prevalence of J-Point Elevation in Sudden Arrhythmic Death Syndrome Families. Journal of the American College of Cardiology, 2011, 58, 286-290.	1.2	108
159	Left ventricular noncompaction and cardiomyopathy: cause, contributor, or epiphenomenon?. Current Opinion in Cardiology, 2008, 23, 171-175.	0.8	106
160	Echocardiographic measurement of right ventricular wall thickness in hypertrophic cardiomyopathy: Relation to clinical and prognostic features. Journal of the American College of Cardiology, 1988, 11, 351-358.	1.2	105
161	Long-Term Outcomes in Hypertrophic Cardiomyopathy Caused by Mutations in the Cardiac Troponin T Gene. Circulation: Cardiovascular Genetics, 2012, 5, 10-17.	5.1	103
162	Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. Journal of the American College of Cardiology, 1993, 22, 498-505.	1.2	101

#	Article	IF	Citations
163	M mode echocardiography in hypertrophic cardiomyopathy: Diagnostic criteria and prediction of obstruction. American Journal of Cardiology, 1980, 45, 6-14.	0.7	97
164	Effect of Mibefradil, a T-Type Calcium Channel Blocker, on Morbidity and Mortality in Moderate to Severe Congestive Heart Failure. Circulation, 2000, 101, 758-764.	1.6	97
165	A common mitochondrial DNA variant associated with susceptibility to dilated cardiomyopathy in two different populations. Lancet, The, 2001, 357, 1265-1267.	6.3	97
166	Myosin binding protein C phosphorylation in normal, hypertrophic and failing human heart muscle. Journal of Molecular and Cellular Cardiology, 2008, 45, 209-216.	0.9	97
167	Amiodarone therapy during pregnancy. American Journal of Cardiology, 1983, 51, 1231-1233.	0.7	93
168	Arrhythmogenic Right Ventricular Cardiomyopathy: Characterization of Left Ventricular Phenotype and Differential Diagnosis With Dilated Cardiomyopathy. Journal of the American Heart Association, 2020, 9, e014628.	1.6	92
169	Signal-averaged electrocardiography in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 1990, 15, 956-961.	1.2	91
170	Mutation of the myosin converter domain alters cross-bridge elasticity. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3557-3562.	3.3	89
171	Detection of hypertrophic cardiomyopathy is improved when using advanced rather than strictly conventional 12-lead electrocardiogram. Journal of Electrocardiology, 2010, 43, 713-718.	0.4	88
172	Molecular basis for clinical heterogeneity in inherited cardiomyopathies due to myopalladin mutations. Human Molecular Genetics, 2012, 21, 2039-2053.	1.4	88
173	Global longitudinal strain is associated with heart failure outcomes in hypertrophic cardiomyopathy. Heart, 2016, 102, 741-747.	1.2	88
174	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. Europace, 2017, 19, euw243.	0.7	86
175	Homozygous Mutation of Desmocollin-2 in Arrhythmogenic Right Ventricular Cardiomyopathy with Mild Palmoplantar Keratoderma and Woolly Hair. Cardiology, 2009, 113, 28-34.	0.6	85
176	Hypertrophic Cardiomyopathy. Current Treatment Options in Cardiovascular Medicine, 2002, 4, 443-453.	0.4	84
177	Nebulette Mutations Are Associated With Dilated Cardiomyopathy and Endocardial Fibroelastosis. Journal of the American College of Cardiology, 2010, 56, 1493-1502.	1.2	84
178	Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. European Heart Journal, 2013, 34, 2529-2537.	1.0	84
179	Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. European Journal of Heart Failure, 2019, 21, 955-964.	2.9	84
180	Significance of signal-averaged electrocardiography in relation to endomyocardial biopsy and ventricular stimulation studies in patients with ventricular tachycardia without clinically apparent heart disease. Journal of the American College of Cardiology, 1989, 14, 372-379.	1.2	83

#	Article	IF	Citations
181	Evidence for autoimmunity to myosin and other heart-specific autoantigens in patients with dilated cardiomyopathy and their relatives. International Journal of Cardiology, 1996, 54, 157-163.	0.8	83
182	Inappropriate major histocompatibility complex expression on cardiac tissue in dilated cardiomyopathy. Relevance for autoimmunity?. Journal of Autoimmunity, 1990, 3, 187-200.	3.0	82
183	Isolated left ventricular noncompaction is rarely caused by mutations in G4.5, Î±-dystrobrevin and FK Binding Protein-12. Molecular Genetics and Metabolism, 2004, 82, 162-166.	0.5	82
184	Sudden Cardiac Death in the Young: A Strategy for Prevention by Targeted Evaluation. Cardiology, 2006, 105, 196-206.	0.6	81
185	Prediction of Sarcomere Mutations in Subclinical Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Imaging, 2014, 7, 863-871.	1.3	80
186	Genetics of Restrictive Cardiomyopathy. Heart Failure Clinics, 2010, 6, 179-186.	1.0	79
187	Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2015, 8, 1022-1031.	1.6	79
188	Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy. Heart, 2007, 93, 372-374.	1.2	78
189	The pathophysiology of advanced heart failure. American Heart Journal, 1998, 135, S216-S230.	1.2	77
190	Arrhythmogenic right ventricular cardiomyopathy/dysplasia on the basis of the revised diagnostic criteria in affected families with desmosomal mutations. European Heart Journal, 2011, 32, 1097-1104.	1.0	77
191	Immunohistologic evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy. Journal of the American College of Cardiology, 2002, 39, 455-462.	1.2	75
192	Cardiomyopathy Mutations Reveal Variable Region of Myosin Converter as Major Element of Cross-Bridge Compliance. Biophysical Journal, 2009, 97, 806-824.	0.2	74
193	Value of the signal-averaged electrocardiogram in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm, 2011, 8, 256-262.	0.3	74
194	Abnormal Cardiac Formation in Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 2014, 7, 241-248.	5.1	74
195	Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. Journal of the American College of Cardiology, 2004, 44, 398-405.	1.2	72
196	The natural history of a genetic subtype ofÂarrhythmogenic right ventricular cardiomyopathy caused by a p.S358L mutation in <scp>TMEM43</scp>. Clinical Genetics, 2013, 83, 321-331.	1.0	72
197	Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 443-451.	2.1	72
198	Arrhythmogenic right ventricular cardiomyopathy caused by deletions in plakophilin-2 and plakoglobin (Naxos disease) in families from Greece and Cyprus: genotype-phenotype relations, diagnostic features and prognosis. European Heart Journal, 2006, 27, 2208-2216.	1.0	71

#	Article	IF	Citations
199	Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart, 2017, 103, 672-678.	1.2	71
200	Desmoplakin missense and non-missense mutations in arrhythmogenic right ventricular cardiomyopathy: Genotype-phenotype correlation. International Journal of Cardiology, 2017, 249, 268-273.	0.8	70
201	Mechanisms of exercise limitation in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 1992, 19, 507-512.	1.2	69
202	Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. European Heart Journal, 2015, 36, 3061-3069.	1.0	69
203	Diagnostic yield of molecular autopsy in patients with sudden arrhythmic death syndrome using targeted exome sequencing. Europace, 2016, 18, 888-896.	0.7	69
204	Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction. American Heart Journal, 1998, 136, 972-981.	1.2	68
205	Appropriate interpretation of the athlete's electrocardiogram saves lives as well as moneyThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2007, 28, 1920-1922.	1.0	67
206	QT dispersion and risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy. American Journal of Cardiology, 1998, 82, 1514-1519.	0.7	66
207	Cardiac Autoantibodies to Myosin and Other Heart-specific Autoantigens in Myocarditis and Dilated Cardiomyopathy. Autoimmunity, 2001, 34, 199-204.	1.2	66
208	Determinants of exercise capacity in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 1989, 13, 1521-1526.	1.2	65
209	Rare NonconservativeLRP6Mutations Are Associated with Metabolic Syndrome. Human Mutation, 2013, 34, 1221-1225.	1.1	64
210	Clinical significance of giant negative T waves in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 1990, 15, 965-971.	1.2	62
211	Effect of biventricular pacing on symptoms and cardiac remodelling in patients with endâ€stage hypertrophic cardiomyopathy. European Journal of Heart Failure, 2008, 10, 507-513.	2.9	62
212	Usefulness of signal-averaged electrocardiogram in idiopathic dilated cardiomyopathy for identifying patients with ventricular arrhythmias. American Journal of Cardiology, 1993, 72, 78-84.	0.7	61
213	Normal passive viscoelasticity but abnormal myofibrillar force generation in human hypertrophic cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2010, 49, 737-745.	0.9	61
214	Echocardiographic and histologic evaluation of the right ventricle in ventricular tachycardias of left bundle branch block morphology without overt cardiac abnormality. American Journal of Cardiology, 1989, 63, 939-944.	0.7	60
215	Effects of long-term oral magnesium chloride replacement in congestive heart failure secondary to coronary artery disease. American Journal of Cardiology, 1993, 72, 1156-1162.	0.7	60
216	Lack of association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and idiopathic dilated cardiomyopathy. Journal of the American College of Cardiology, 1995, 25, 1627-1631.	1.2	60

#	Article	IF	Citations
217	Desmoglein-2 interaction is crucial for cardiomyocyte cohesion and function. Cardiovascular Research, 2014, 104, 245-257.	1.8	59
218	Local abnormalities of right ventricular depolarization after repair of tetralogy of Fallot: A basis for ventricular arrhythmia. American Journal of Cardiology, 1985, 55, 522-525.	0.7	58
219	Growth Hormone Therapy and Growth in Children with Noonanâ€™s Syndrome: Results of 3 Yearsâ€™ Follow-Up*. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1953-1956.	1.8	58
220	The use of phosphateâ€affinity SDSâ€PAGE to measure the cardiac troponin I phosphorylation site distribution in human heart muscle. Proteomics - Clinical Applications, 2009, 3, 1371-1382.	0.8	58
221	Prognostic value of thallium-201 perfusion defects in idiopathic dilated cardiomyopathy. American Journal of Cardiology, 1991, 67, 188-193.	0.7	57
222	Exercise-Induced T-Wave Alternans as a Marker of High Risk in Patients With Hypertrophic Cardiomyopathy. Japanese Circulation Journal, 1997, 61, 650-656.	1.0	57
223	Filamin C variants are associated with a distinctive clinical and immunohistochemical arrhythmogenic cardiomyopathy phenotype. International Journal of Cardiology, 2020, 307, 101-108.	0.8	56
224	Mutational Heterogeneity, Modifier Genes, and Environmental Influences Contribute to Phenotypic Diversity of Arrhythmogenic Cardiomyopathy. Circulation: Cardiovascular Genetics, 2010, 3, 323-330.	5.1	55
225	Unequal allelic expression of wild-type and mutated Î²-myosin in familial hypertrophic cardiomyopathy. Basic Research in Cardiology, 2011, 106, 1041-1055.	2.5	55
226	Diagnosis of apical hypertrophic cardiomyopathy: T-wave inversion and relative but not absolute apical left ventricular hypertrophy. International Journal of Cardiology, 2015, 183, 143-148.	0.8	55
227	Hypertrophic cardiomyopathy-related Î²-myosin mutations cause highly variable calcium sensitivity with functional imbalances among individual muscle cells. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H1242-H1251.	1.5	54
228	Phenotype and prognostic correlations of the converter region mutations affecting the Î² myosin heavy chain. Heart, 2015, 101, 1047-1053.	1.2	54
229	Q waves in hypertrophic cardiomyopathy in relation to the distribution and severity of right and left ventricular hypertrophy. Journal of the American College of Cardiology, 1990, 16, 368-374.	1.2	53
230	Relation of left ventricular function and prognosis in hypertrophic cardiomyopathy: An angiographic study. Journal of the American College of Cardiology, 1985, 5, 1064-1074.	1.2	52
231	Echocardiographic assessment of the right ventricle in Ebstein's anomaly: Relation to clinical outcome. Journal of the American College of Cardiology, 1986, 8, 627-635.	1.2	51
232	Fractal Analysis of Myocardial Trabeculations in 2547 Study Participants: Multi-Ethnic Study of Atherosclerosis. Radiology, 2015, 277, 707-715.	3.6	50
233	Left Lower Lobe Ventilation Is Reduced in Patients with Cardiomegaly in the Supine But Not the Prone Position. The American Review of Respiratory Disease, 1990, 141, 150-155.	2.9	49
234	Current medical therapy for advanced heart failure. American Heart Journal, 1998, 135, S231-S248.	1.2	49

#	Article	IF	Citations
235	Arrhythmogenic right ventricular cardiomyopathy: clinical registry and database, evaluation of therapies, pathology registry, DNA banking. European Heart Journal, 2004, 25, 531-534.	1.0	48
236	A novel desmocollin-2 mutation reveals insights into the molecular link between desmosomes and gap junctions. Heart Rhythm, 2011, 8, 711-718.	0.3	48
237	Arrhythmogenic right ventricular cardiomyopathy mimics: role of cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 16.	1.6	48
238	Decreased Heart Rate Variability in Patients with Congestive Heart Failure and Chronotropic Incompetence. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 477-483.	0.5	47
239	The pathophysiology of advanced heart failure. Heart and Lung: Journal of Acute and Critical Care, 1999, 28, 87-101.	0.8	47
240	Left ventricular strain and untwist in hypertrophic cardiomyopathy: Relation to exercise capacity. American Heart Journal, 2010, 159, 825-832.	1.2	47
241	Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy. JAMA Cardiology, 2019, 4, 230.	3.0	47
242	Mechanistic insights into arrhythmogenic right ventricular cardiomyopathy caused by desmocollin-2 mutations. Cardiovascular Research, 2011, 90, 77-87.	1.8	46
243	Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy. Journal of Interventional Cardiac Electrophysiology, 2002, 6, 482-486.	0.9	45
244	The relation of ventricular arrhythmia electrophysiological characteristics to cardiac phenotype and circadian patterns in hypertrophic cardiomyopathy. Europace, 2012, 14, 724-733.	0.7	45
245	Recognition and Optimum Management of Myocarditis. Drugs, 1996, 52, 515-525.	4.9	44
246	Sudden Death From Genetic and Acquired Cardiomyopathies. Circulation, 2012, 125, 1563-1576.	1.6	44
247	Recurrent missense mutations in TMEM43 (ARVD5) due to founder effects cause arrhythmogenic cardiomyopathies in the UK and Canada. European Heart Journal, 2013, 34, 1002-1011.	1.0	44
248	Imaging Phenotype Versus Genotype in Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Imaging, 2011, 4, 156-168.	1.3	43
249	Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. Circulation, 2021, 144, 1600-1611.	1.6	43
250	Immunosuppression for Myocarditis. New England Journal of Medicine, 1995, 333, 312-313.	13.9	42
251	Usefulness of N-Terminal Pro-B-Type Natriuretic Peptide Levels to Predict Exercise Capacity in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2006, 98, 515-519.	0.7	42
252	Family History of Premature Death and Risk of Early Onset Cardiovascular Disease. Journal of the American College of Cardiology, 2012, 60, 814-821.	1.2	42

#	Article	IF	Citations
253	Electrical and Structural Substrate of Arrhythmogenic Right Ventricular Cardiomyopathy Determined Using Noninvasive Electrocardiographic Imaging and Late Gadolinium Magnetic Resonance Imaging. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	42
254	The molecular phenotype of human cardiac myosin associated with hypertrophic obstructive cardiomyopathy. Cardiovascular Research, 2008, 79, 481-491.	1.8	41
255	The natural history of hypertrophic cardiomyopathy. Current Problems in Cardiology, 1981, 6, 1-26.	1.1	40
256	Arrhythmias in Dilated and Hypertrophic Cardiomyopathy. Medical Clinics of North America, 1984, 68, 983-1000.	1.1	40
257	Dilated cardiomyopathy: a genetically heterogeneous disease. Lancet, The, 2002, 360, 654-655.	6.3	40
258	Exercise: friend or foe?. Nature Reviews Cardiology, 2013, 10, 495-507.	6.1	39
259	Arrhythmic risk assessment in genotyped families with arrhythmogenic right ventricular cardiomyopathy. Europace, 2016, 18, 610-616.	0.7	39
260	Comparison of the Functional Significance of Left Ventricular Hypertrophy in Hypertrophic Cardiomyopathy and Glycogenosis Type III. American Journal of Cardiology, 1997, 79, 834-838.	0.7	38
261	Desmoplakin disease in arrhythmogenic right ventricular cardiomyopathy: early genotypeâ€“phenotype studiesThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2005, 26, 1582-1584.	1.0	38
262	Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, e001974.	1.6	38
263	The digoxin-amiodarone interaction. Cardiovascular Drugs and Therapy, 1989, 3, 25-28.	1.3	37
264	Task force III: Hypertrophic cardiomyopathy, other myopericardial diseases and mitral valve prolapse. Journal of the American College of Cardiology, 1985, 6, 1215-1217.	1.2	36
265	Regional thallium-201 washout and myocardial hypertrophy in hypertrophic cardiomyopathy and its relation to exertional chest pain. American Journal of Cardiology, 1993, 72, 211-217.	0.7	36
266	A prospective case-control study of antibodies to Coxsackie B virus in idiopathic dilated cardiomyopathy. Journal of the American College of Cardiology, 1994, 23, 593-598.	1.2	36
267	Comparison of clinical, morphological, and prognostic features in hypertrophic cardiomyopathy between japanese and western patients. Clinical Cardiology, 1992, 15, 833-837.	0.7	35
268	Is there increased sympathetic activity in patients with hypertrophic cardiomyopathy?. Journal of the American College of Cardiology, 1995, 26, 472-480.	1.2	35
269	Mutations in PDLIM3 and MYOZ1 encoding myocyte Z line proteins are infrequently found in idiopathic dilated cardiomyopathy. Molecular Genetics and Metabolism, 2007, 90, 435-440.	0.5	35
270	Dynamic electrocardiographic changes in patients with arrhythmogenic right ventricular cardiomyopathy. Heart, 2010, 96, 516-522.	1.2	35

#	Article	IF	Citations
271	Ablation compared with drug therapy for recurrent ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy: Results from a multicenter study. Heart Rhythm, 2019, 16, 536-543.	0.3	35
272	Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy. European Heart Journal, 2006, 27, 3073-3073.	1.0	34
273	Left-dominant arrhythmogenic cardiomyopathy in a large family: Associated desmosomal or nondesmosomal genotype?. Heart Rhythm, 2013, 10, 548-559.	0.3	34
274	Myofibrillar Ca2+ sensitivity is uncoupled from troponin I phosphorylation in hypertrophic obstructive cardiomyopathy due to abnormal troponin T. Cardiovascular Research, 2013, 97, 500-508.	1.8	34
275	Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment. Cmaj, 2013, 185, 127-134.	0.9	34
276	Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, .	1.6	34
277	Myoarchitectural disarray of hypertrophic cardiomyopathy begins preâ€birth. Journal of Anatomy, 2019, 235, 962-976.	0.9	34
278	Value of Exercise Testing in Assessing Clinical State and Prognosis in Hypertrophic Cardiomyopathy. Cardiology in Review, 2001, 9, 70-76.	0.6	33
279	The variation of the sarcolipin gene (SLN) in atrial fibrillation, long QT syndrome and sudden arrhythmic death syndrome. Clinica Chimica Acta, 2007, 375, 87-91.	0.5	33
280	Novel missense mutations in exon 15 of desmoglein-2: Role of the intracellular cadherin segment in arrhythmogenic right ventricular cardiomyopathy?. Heart Rhythm, 2010, 7, 1446-1453.	0.3	33
281	Variability of ventricular arrhythmias in hypertrophic cardiomyopathy and implications for treatment. American Journal of Cardiology, 1986, 58, 615-618.	0.7	32
282	Psychiatric disorders in hypertrophic cardiomyopathy. General Hospital Psychiatry, 2008, 30, 49-54.	1.2	32
283	Prognostic significance of spectral turbulence analysis of the signal-averaged electrocardiogram in patients with idiopathic dilated cardiomyopathy. American Journal of Cardiology, 1995, 75, 494-497.	0.7	31
284	Disparate effects of different mutations in plakoglobin on cell mechanical behavior. Cytoskeleton, 2008, 65, 964-978.	4.4	31
285	Arrhythmogenic Left Ventricular Cardiomyopathy. Circulation, 2009, 120, 2613-2614.	1.6	31
286	Frequency of genetic variants associated with arrhythmogenic right ventricular cardiomyopathy in the genome aggregation database. European Journal of Human Genetics, 2018, 26, 1312-1318.	1.4	31
287	Ambulatory Assessment of the QT Interval in Patients with Hypertrophic Cardiomyopathy: Risk Stratification and Effect of Low Dose Amiodarone. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 2222-2227.	0.5	30
288	Current medical therapy for advanced heart failure. Heart and Lung: Journal of Acute and Critical Care, 2000, 29, 16-32.	0.8	30

#	Article	IF	Citations
289	Functional assessment of compound mutations in the KCNQ1 and KCNH2 genes associated with long QT syndrome. Heart Rhythm, 2005, 2, 1238-1249.	0.3	30
290	Molecular changes in the heart of a severe case of arrhythmogenic right ventricular cardiomyopathy caused by a desmoglein-2 null allele. Cardiovascular Pathology, 2012, 21, 275-282.	0.7	30
291	Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy. Heart, 2017, 103, 300-306.	1.2	30
292	Effect of amiodarone on left ventricular ejection and filling in hypertrophic cardiomyopathy as assessed by radionuclide angiography. American Journal of Cardiology, 1984, 54, 1054-1058.	0.7	29
293	The embryological basis of subclinical hypertrophic cardiomyopathy. Scientific Reports, 2016, 6, 27714.	1.6	29
294	Association of cytomegalovirus infection with post-transplantation cardiac rejection as studied using the polymerase chain reaction. Journal of Medical Virology, 1994, 42, 396-404.	2.5	28
295	Free radicals irreversibly decrease Ca2+ currents in isolated guinea-pig ventricular myocytes. European Journal of Pharmacology - Environmental Toxicology and Pharmacology Section, 1995, 292, 337-340.	0.8	28
296	Genes and disease expression in hypertrophic cardiomyopathy. Lancet, The, 1998, 352, 1162-1163.	6.3	28
297	Sudden death in young athletes: HCM or ARVC?. Cardiovascular Drugs and Therapy, 2002, 16, 11-17.	1.3	27
298	A Novel Myosin Essential Light Chain Mutation Causes Hypertrophic Cardiomyopathy with Late Onset and Low Expressivity. Biochemistry Research International, 2012, 2012, 1-6.	1.5	27
299	The Role of CAV3 in Longâ€“QT Syndrome. Circulation: Cardiovascular Genetics, 2013, 6, 452-461.	5.1	27
300	Effects of propafenone on calcium currents in single ventricular myocytes of guineaâ€pig. British Journal of Pharmacology, 1993, 109, 178-182.	2.7	26
301	Class III Antiarrhythmics in Overdose. Drug Safety, 1993, 9, 450-462.	1.4	25
302	T Wave Complexity in Patients with Hypertrophic Cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 2382-2386.	0.5	25
303	Calcium channel blockers in cardiac failure. Progress in Cardiovascular Diseases, 1998, 41, 191-206.	1.6	25
304	Reflex Responses of Venous Capacitance Vessels in Patients with Hypertrophic Cardiomyopathy. Clinical Science, 1998, 94, 339-346.	1.8	25
305	Variable Interatrial Conduction Illustrated in a Hypertrophic Cardiomyopathy Population. Annals of Noninvasive Electrocardiology, 2007, 12, 227-236.	0.5	25
306	The utility of magnetic resonance imaging in the evaluation of arrhythmogenic right ventricular cardiomyopathy. Current Opinion in Cardiology, 2008, 23, 38-45.	0.8	25

#	Article	IF	Citations
307	Unique epidermolytic bullous dermatosis with associated lethal cardiomyopathy related to novel desmoplakin mutations. Journal of Cutaneous Pathology, 2009, 36, 553-559.	0.7	25
308	Prognostic significance of radionuclide-assessed diastolic function in hypertrophic cardiomyopathy. American Journal of Cardiology, 1990, 65, 478-482.	0.7	24
309	Myocardial magnesium depletion associated with prolonged hypomagnesemia: A longitudinal study in heart transplant recipients. Journal of the American College of Cardiology, 1992, 20, 806-812.	1.2	24
310	Late-Onset Hypertrophic Cardiomyopathy Caused by a Mutation in the Cardiac Troponin T Gene. New England Journal of Medicine, 1999, 341, 1855-1856.	13.9	24
311	Arrhythmogenic Right Ventricular Dyspiasia/Cardiomyopathy:.. Journal of Cardiovascular Electrophysiology, 2000, 11, 827-832.	0.8	24
312	Elevated serum levels of soluble interleukin-2 receptor, neopterin and Î²-2-microglobulin in idiopathic dilated cardiomyopathy: relation to disease severity and autoimmune pathogenesis. European Journal of Heart Failure, 2001, 3, 155-163.	2.9	24
313	Fractal correlation properties of R-R interval dynamics in asymptomatic relatives of patients with dilated cardiomyopathyâ˜†. European Journal of Heart Failure, 2002, 4, 151-158.	2.9	24
314	Dual Chamber Pacing in Hypertrophic Cardiomyopathy: Long-Term Effects on Diastolic Function. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 1433-1440.	0.5	24
315	Clinical Significance of Epsilon Waves in Arrhythmogenic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2015, 26, 1204-1210.	0.8	24
316	Electrophysiologic and antiarrhythmic actions of bepridil. American Journal of Cardiology, 1985, 55, 1513-1519.	0.7	23
317	Prevalence of Sequence Variants in the RAS-Mitogen Activated Protein Kinase Signaling Pathway in Pre-Adolescent Children With Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 2012, 5, 317-326.	5.1	23
318	RNA sequencing-based transcriptome profiling of cardiac tissue implicates novel putative disease mechanisms in FLNC-associated arrhythmogenic cardiomyopathy. International Journal of Cardiology, 2020, 302, 124-130.	0.8	23
319	Comparison of clinical features in patients â‰¥60 years of age to those â‰40 years of age with hypertrophic cardiomyopathy. American Journal of Cardiology, 1990, 66, 875-878.	0.7	22
320	HLA and immunoglobulin polymorphisms in idiopathic dilated cardiomyopathy. Human Immunology, 1992, 35, 193-199.	1.2	21
321	Micro-exons of the cardiac myosin binding protein C gene: flanking introns contain a disproportionately large number of hypertrophic cardiomyopathy mutations. European Journal of Human Genetics, 2008, 16, 1062-1069.	1.4	21
322	Atriobiventricular pacing improves exercise capacity in patients with heart failure and intraventricular conduction delay. Journal of the American College of Cardiology, 2003, 41, 582-588.	1.2	20
323	ActualizaciÃ³n en miocardiopatÃa arritmogÃ©nica del ventrÃculo derecho: genÃ©tica, diagnÃ³stico, manifestaciones clÃnicas y estratificaciÃ³n de riesgo. Revista Espanola De Cardiologia, 2004, 57, 757-767.	0.6	20
324	Reversal of Inappropriate Peripheral Vascular Responses in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2005, 46, 883-892.	1.2	20

#	Article	IF	Citations
325	The emerging role of cardiovascular magnetic resonance in refining the diagnosis of hypertrophic cardiomyopathy. Nature Reviews Cardiology, 2009, 6, 166-167.	6.1	20
326	Myocardial Crypts. Circulation: Cardiovascular Imaging, 2012, 5, 431-432.	1.3	20
327	Cellular mechanisms underlying the increased disease severity seen for patients with long QT syndrome caused by compound mutations in KCNQ1. Biochemical Journal, 2014, 462, 133-142.	1.7	20
328	Electrocardiographic differentiation of idiopathic right ventricular outflow tract ectopy from early arrhythmogenic right ventricular cardiomyopathy. Europace, 2017, 19, euw018.	0.7	20
329	â€˜Pseudoâ€™ systolic anterior motion in patients with hypertensive heart disease. European Heart Journal, 1983, 4, 838-845.	1.0	19
330	Abnormal septal convexity into the left ventricle occurs in subclinical hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 64.	1.6	19
331	Inverted U-Shaped Relation Between the Risk of Sudden Cardiac Death and Maximal Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	19
332	Risk-Benefit Assessment of Amiodarone in the Treatment of Cardiac Arrhythmias. Drug Safety, 1990, 5, 286-304.	1.4	18
333	Functional effects of the DCM mutant Gly159Asp Troponin C in skinned muscle fibres. Pflugers Archiv European Journal of Physiology, 2007, 453, 771-776.	1.3	18
334	Skeletal muscle involvement in cardiomyopathies. Journal of Cardiovascular Medicine, 2013, 14, 837-861.	0.6	18
335	Familial dilated cardiomyopathy diagnosis is commonly overlooked at the time of transplant listing. Journal of Heart and Lung Transplantation, 2016, 35, 474-480.	0.3	18
336	Epicardial myocardial strain abnormalities may identify the earliest stages of arrhythmogenic cardiomyopathy. International Journal of Cardiovascular Imaging, 2016, 32, 593-601.	0.7	18
337	Survival After Heart Transplantation in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. Journal of Cardiac Failure, 2017, 23, 107-112.	0.7	18
338	Prediction of ventricular arrhythmia and sudden death in arrhythmogenic right ventricular cardiomyopathy. European Heart Journal, 2019, 40, 1859-1861.	1.0	18
339	Assessment of the diagnostic value of head-up tilt testing in the evaluation of syncope in hypertrophic cardiomyopathy. American Journal of Cardiology, 1994, 73, 601-604.	0.7	17
340	8. Molecular Genetics of Familial Cardiomyopathies. Advances in Genetics, 1997, 35, 285-324.	0.8	17
341	Diagnostic value of contrast echocardiography in Tako-Tsubo cardiomyopathy. Archives of Cardiovascular Diseases, 2010, 103, 447-453.	0.7	16
342	135â€…Novel Hybrid Positron Emission Tomography - Magnetic Resonance (PET-MR) Multi-modality Inflammatory Imaging has Improved Diagnostic Accuracy for Detecting Cardiac Sarcoidosis. Heart, 2014, 100, A80.1-A80.	1.2	16

#	Article	IF	Citations
343	Arrhythmias in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 1991, 2, 516-524.	0.8	15
344	Is QT Dispersion Associated with Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy?. Annals of Noninvasive Electrocardiology, 2001, 6, 209-215.	0.5	15
345	Significance of Maximal and Regional Left Ventricular Wall Thickness in Association With Arrhythmic Events in Patients With Hypertrophic Cardiomyopathy. Circulation Journal, 2010, 74, 531-537.	0.7	15
346	Immunopathogenesis of dilated cardiomyopathies. Current Opinion in Cardiology, 1995, 10, 306-311.	0.8	14
347	Acute changes in atrial natriuretic peptide, insulin-like growth factor-1, and lactate levels during left anterior descending coronary artery angioplasty. American Heart Journal, 1995, 130, 717-722.	1.2	14
348	Beta-blocker therapy in advanced heart failure: clinical characteristics and long-term outcomes. European Journal of Heart Failure, 1999, 1, 81-88.	2.9	14
349	PACING IN HYPERTROPHIC CARDIOMYOPATHY. Cardiology Clinics, 2000, 18, 67-79.	0.9	14
350	T-Wave Alternans and Left Ventricular Wall Thickness in Predicting Arrhythmic Risk in Patients With Hypertrophic Cardiomyopathy. Circulation Journal, 2010, 74, 1197-1204.	0.7	14
351	Lamin mutation location predicts cardiac phenotype severity: combined analysis of the published literature. Open Heart, 2018, 5, e000915.	0.9	14
352	Assessment of diastolic filling indexes obtained by radionuclide ventriculography. American Journal of Cardiology, 1990, 65, 226-230.	0.7	13
353	Human Chagasic Disease is Not Associated With an Antiheart Humoral Response. American Journal of Cardiology, 1997, 79, 1135-1137.	0.7	13
354	Comparison of Prognostic Value of Tissue Doppler Imaging in Carcinoid Heart Disease Versus the Value in Patients With the Carcinoid Syndrome but Without Carcinoid Heart Disease. American Journal of Cardiology, 2010, 105, 527-531.	0.7	13
355	Feasibility and Significance of Preclinical Diagnosis in Hypertrophic Cardiomyopathy. Cardiology in Review, 2015, 23, 297-302.	0.6	13
356	The ventricular ectopic QRS interval (VEQSI): Diagnosis of arrhythmogenic right ventricular cardiomyopathy in patients with incomplete disease expression. Heart Rhythm, 2016, 13, 1504-1512.	0.3	13
357	Left ventricular diastolic characteristics of cardiac sarcoidosis. American Journal of Cardiology, 1986, 58, 1126-1127.	0.7	12
358	Long-term effects of amiodarone on hepatic function. American Journal of Cardiology, 1989, 64, 95-96.	0.7	12
359	Validation of bedside measurements of absolute human renal blood flow by a continuous thermodilution technique. Critical Care Medicine, 1992, 20, 659-664.	0.4	12
360	Creatine kinase isoforms as circulating markers of deterioration in idiopathic dilated cardiomyopathy. Clinical Cardiology, 1997, 20, 55-60.	0.7	12

#	Article	IF	Citations
361	Mutation screening ofÂtheÂPTPN11 gene inÂhypertrophic cardiomyopathy. European Journal of Medical Genetics, 2006, 49, 426-430.	0.7	12
362	Evaluation of Suspected Right Ventricular Pathology in the Athlete. Progress in Cardiovascular Diseases, 2012, 54, 397-406.	1.6	12
363	Biventricular pacemaker therapy improves exercise capacity in patients with nonâ€obstructive hypertrophic cardiomyopathy via augmented diastolic filling on exercise. European Journal of Heart Failure, 2020, 22, 1263-1272.	2.9	12
364	Usefulness of Signal-Averaged Electrocardiography in Evaluation of Idiopathic-Dilated Cardiomyopathy in Families. American Journal of Cardiology, 1997, 79, 1203-1207.	0.7	11
365	AblaciÃ³n septal alcohÃ³lica en la miocardiopatÃa hipertrÃ³fica, una oportunidad para aprovechar. Revista Espanola De Cardiologia, 2012, 65, 314-318.	0.6	11
366	Dynamic Conduction and Repolarisation Changes in Early Arrhythmogenic Right Ventricular Cardiomyopathy versus Benign Outflow Tract Ectopy Demonstrated by High Density Mapping & Paced Surface ECG Analysis. PLoS ONE, 2014, 9, e99125.	1.1	11
367	Reperfusion arrhythmias are rare during acute myocardial infarction and thrombolysis in man. International Journal of Cardiology, 1990, 29, 205-213.	0.8	10
368	Effects of adenosine on atrial repolarization in the transplanted human heart. American Journal of Cardiology, 1993, 71, 248-251.	0.7	10
369	Increased ventricular sialylation in patients with heart failure secondary to ischemic heart disease. Clinical Cardiology, 1997, 20, 455-458.	0.7	10
370	Partial join order optimization in the paraccel analytic database. , 2009, , .		10
371	Corrigendum to: 'Recommendations for interpretation of 12-lead electrocardiogram in the athlete' [Eur Heart J 2010;31:243-259]. European Heart Journal, 2010, 31, 379-379.	1.0	10
372	Cardiac Magnetic Resonance Imaging and Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy. Circulation, 2014, 130, 455-457.	1.6	10
373	Heart failure in patients with arrhythmogenic right ventricular cardiomyopathy: Genetic characteristics. International Journal of Cardiology, 2019, 286, 99-103.	0.8	10
374	Exercise gas exchange responses in the differentiation of pathologic and physiologic left ventricular hypertrophy. Medicine and Science in Sports and Exercise, 1999, 31, 1237-1241.	0.2	10
375	Noninvasive Recording of the His Bundle Electrogram: Value of Supplementary Verapamil. PACE - Pacing and Clinical Electrophysiology, 1981, 4, 281-288.	0.5	9
376	Is there a role for epoprostenol in the management of heart failure?. American Journal of Cardiology, 1995, 75, 44A-50A.	0.7	9
377	Can the Assessment of Dynamic QT Dispersion on Exercise Electrocardiogram Predict Sudden Cardiac Death in Hypertrophic Cardiomyopathy?. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 1953-1956.	0.5	9
378	The Science of Uncertainty and the Art of Probability. Circulation, 2009, 119, 1697-1699.	1.6	9

#	Article	IF	Citations
379	Reconciling the Protean Manifestations of Arrhythmogenic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2010, 3, 566-570.	2.1	9
380	Angina pectoris with normal coronary arteriograms. Coronary Artery Disease, 1992, 3, 547-554.	0.3	8
381	Comparison of time domain and spectral turbulence analysis of the signalâ€averaged electrocardiogram for the prediction of prognosis in idiopathic dilated cardiomyopathy. Clinical Cardiology, 1996, 19, 800-808.	0.7	8
382	Arrhythmias and sudden death in hypertrophic cardiomyopathy. Journal of Interventional Cardiac Electrophysiology, 2002, 6, 26-31.	0.9	8
383	Non-invasive risk stratification in hypertrophic cardiomyopathy: don't throw out the baby with the bathwater. European Heart Journal, 2008, 29, 1600-1602.	1.0	8
384	The role of ACE inhibitors in the treatment of arrhythmias. Clinical Cardiology, 2009, 13, VII-49-VII-52.	0.7	8
385	Risk score for the exclusion of arrhythmic events in arrhythmogenic right ventricular cardiomyopathy at first presentation. International Journal of Cardiology, 2019, 290, 100-105.	0.8	8
386	Arrhythmogenic right ventricular cardiomyopathy in Boxer dogs: the diagnosis as a link to the human disease. Acta Myologica, 2017, 36, 135-150.	1.5	8
387	Lowâ€Đose Amiodarone for the Treatment of Arrhythmias in Hypertrophic Cardiomyopathy. Journal of Clinical Pharmacology, 1989, 29, 436-438.	1.0	7
388	Diagnostic Value of Endomyocardial Biopsies of the Right Ventricular Septum in Arrhythmias Originating from the Right Ventricle.. International Heart Journal, 1996, 37, 195-202.	0.6	7
389	Update in Arrhythmogenic Right Ventricular Cardiomyopathy: Genetic, Clinical Presentation, and Risk Stratification. Revista Espanola De Cardiologia (English Ed), 2004, 57, 757-767.	0.4	7
390	From Teare to the Present Day: A Fifty Year Odyssey in Hypertrophic Cardiomyopathy, a Paradigm for the Logic of the Discovery Process. Revista Espanola De Cardiologia (English Ed), 2008, 61, 1239-1244.	0.4	7
391	Insights and challenges in hypertrophic cardiomyopathy, 2012. Herzschrittmachertherapie Und Elektrophysiologie, 2012, 23, 174-185.	0.3	7
392	When Rare Illuminates Common: How Cardiocutaneous Syndromes Transformed Our Perspective on Arrhythmogenic Cardiomyopathy. Cell Communication and Adhesion, 2014, 21, 3-11.	1.0	7
393	Failure to Predict Development of Atrioventricular Block with Electrophysiological Testing Supplemented by Ajmaline. PACE - Pacing and Clinical Electrophysiology, 1980, 3, 666-669.	0.5	6
394	Hypertrophic cardiomyopathyâ€”the clinical challenge of managing a hereditary heart condition. European Heart Journal, 2003, 24, 496-498.	1.0	6
395	Complementary Role of Echocardiography and Cardiac Magnetic Resonance in the Non-Invasive Evaluation of Suspected Arrhythmogenic Right Ventricular Cardiomyopathy. Journal of Interventional Cardiac Electrophysiology, 2004, 11, 15-17.	0.6	6
396	Pel-Ebstein Fever Coinciding with Cyclical Haemolytic Anaemia and Splenomegaly in a Patient with Hodgkin's Disease. Scandinavian Journal of Haematology, 2009, 23, 378-380.	0.0	6

#	Article	IF	Citations
397	Alcohol Septal Ablation in Hypertrophic Cardiomyopathy: An Opportunity to Be Taken. Revista Espanola De Cardiologia (English Ed), 2012, 65, 314-318.	0.4	6
398	94â€...Percutaneous Mitral Repair in Hypertrophic Cardiomyopathy: Abstract 94 Table 1. Heart, 2014, 100, A54-A55.	1.2	6
399	Myocardial Inflammation and Sudden Death in the Inherited Cardiomyopathies. Canadian Journal of Cardiology, 2022, 38, 427-438.	0.8	6
400	The epidemiology of heart failure secondary to coronary artery disease. Coronary Artery Disease, 1998, 9, 625-628.	0.3	5
401	Beta adrenergic blockers in chronic congestive cardiac failure: a call for action. European Journal of Internal Medicine, 2002, 13, 96-100.	1.0	5
402	Hypertrophic cardiomyopathy: a 50th anniversary. Heart, 2007, 94, 1247-1248.	1.2	5
403	How should hypertrophic cardiomyopathy be classified?. Circulation: Cardiovascular Genetics, 2009, 2, 87-89.	5.1	5
404	Identification of an elusive spliceogenic MYBPC3 variant in an otherwise genotype-negative hypertrophic cardiomyopathy pedigree. Scientific Reports, 2022, 12, 7284.	1.6	5
405	HL-A and hypertrophic cardiomyopathy. American Heart Journal, 1980, 99, 542.	1.2	4
406	Stability of plasma amiodarone levels during chronic oral therapy. Cardiovascular Drugs and Therapy, 1990, 4, 529-530.	1.3	4
407	Occult Anomalous Pulmonary Venous Drainage. Circulation, 2002, 105, E27-8.	1.6	4
408	Hypertrophic cardiomyopathy: Management issues in the new millennium. Current Cardiology Reports, 2002, 4, 226-232.	1.3	4
409	What is the mechanism of abnormal blood pressure response on exercise in hypertrophic cardiomyopathy?. Journal of the American College of Cardiology, 2003, 41, 2102.	1.2	4
410	Myocarditis and the military patient. Journal of the Royal Army Medical Corps, 2015, 161, 275-282.	0.8	4
411	Standing on the Shoulders of Giants: J.A.P. ParÃ© and the Birth of Cardiovascular Genetics. Canadian Journal of Cardiology, 2015, 31, 1305-1308.	0.8	4
412	Ethnic differences in out-of-hospital cardiac arrest among Middle Eastern Arabs and North African populations living in Qatar. Ethnicity and Health, 2021, 26, 460-469.	1.5	4
413	Molecular motors in the heart. Essays in Biochemistry, 2000, 35, 145-158.	2.1	4
414	Hypertrophic cardiomyopathy: Measurement of cation uptake. American Journal of Cardiology, 1981, 47, 409.	0.7	3

#	Article	IF	Citations
415	Sudden death after correction of tetralogy of Fallot: A clinical pathological study. American Journal of Cardiology, 1982, 49, 998.	0.7	3
416	Effects of amiodarone on the kinetics of antipyrine. American Journal of Cardiology, 1989, 63, 991-992.	0.7	3
417	Use of Spectral Turbulence Analysis for the Identification of Patients at High Risk for Ventricular Fibrillation and Sudden Death in Patients with Hypertrophic Cardiomyopathy. Cardiology, 1998, 90, 79-82.	0.6	3
418	Sudden death and hypertrophic cardiomyopathy. Lancet, The, 2001, 357, 1975-1976.	6.3	3
419	Understanding the Myocardial Architecture of Hypertrophic Cardiomyopathy for Clinical Care. Journal of the American College of Cardiology, 2019, 73, 2503-2505.	1.2	3
420	Sudden death in hypertrophic cardiomyopathy associated with 46,XY pure gonadal dysgenesis. American Heart Journal, 1988, 116, 1099-1101.	1.2	2
421	Arrhythmogenic right ventricular cardiomyopathy: diagnosis and management. International Journal of Cardiology, 2001, 81, 18-20.	0.8	2
422	The role of exercise testing in the evaluation of the patient with hypertrophic cardiomyopathy. Current Cardiology Reports, 2001, 3, 152-159.	1.3	2
423	Evidence for reduced troponin I phosphorylation and altered troponin function in patients with hypertrophic obstructive cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2006, 40, 939.	0.9	2
424	The Implications of Inheritance for Clinical Management. Circulation: Cardiovascular Genetics, 2012, 5, 467-476.	5.1	2
425	Familial Hypertrophic Cardiomyopathy: Unequal Expression of Mutant and Wildtype Myosin in Individual Myocytes as Trigger for Functional Impairment of the Heart?. Biophysical Journal, 2014, 106, 644a-645a.	0.2	2
426	126â€…Advanced Assessment of Cardiac Morphology and Prediction of Gene Carriage by CMR in Hypertrophic Cardiomyopathy - The HCMNET/UCL Collaboration. Heart, 2014, 100, A72-A73.	1.2	2
427	Successful launch of a comprehensive European registry for the cardiomyopathies. European Heart Journal, 2016, 37, 174-176.	1.0	2
428	No major role for rare plectin variants in arrhythmogenic right ventricular cardiomyopathy. PLoS ONE, 2018, 13, e0203078.	1.1	2
429	Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations. Journal of Molecular and Cellular Cardiology, 1992, 24, S77.	0.9	1
430	Pitfalls of Pacemaker Treatment for Hypertrophic Cardiomyopathy. Journal of Interventional Cardiology, 1996, 9, 405-412.	0.5	1
431	Title is missing!. Journal of Interventional Cardiac Electrophysiology, 1997, 1, 229-232.	0.9	1
432	Hypertrophic cardiomyopathy. Evidence-based Cardiovascular Medicine, 1998, 2, 89-91.	0.0	1

#	Article	IF	Citations
433	Organ-Specific Autoimmunity Involvement in Cardiovascular Disease. Handbook of Systemic Autoimmune Diseases, 2003, , 19-39.	0.1	1
434	The new European definition of cardiomyopathies: which space for muscle dystrophies?: reply. European Heart Journal, 2008, 29, 1592-1592.	1.0	1
435	Genetics of Dilated Cardiomyopathy: Risk of Conduction Defects and Sudden Cardiac Death. Cardiac Electrophysiology Clinics, 2010, 2, 599-609.	0.7	1
436	Clinical Impact of Genetics in Arrhythmogenic Cardiomyopathy. Cardiac Electrophysiology Clinics, 2011, 3, 205-215.	0.7	1
437	Corrigendum to: 'HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies' [Europace 2011;13:1077-109, doi: 10.1093/europace/eur245]. Europace, 2012, 14, 277-277.	0.7	1
438	MYH7-Mutation Associated Allelic Imbalance in Familial Hypertrophic Cardiomyopathy: Molecular Mechanisms and Correlation with Disease Prognosis. Biophysical Journal, 2012, 102, 613a.	0.2	1
439	Support for Routine Use of Metabolic Stress Testing in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2012, 109, 1534-1535.	0.7	1
440	Are We Nearly There Yet? Progress in the Prevention of Sudden Cardiac Death in the Young. Cardiology, 2014, 127, 265-274.	0.6	1
441	89â€…The Electrocardiographic Phenotype in Athletes with Hypertrophic Cardiomyopathy: Implications for Pre-Participation Cardiovascular Evaluation Using Electrocardiography. Heart, 2014, 100, A51-A51.	1.2	1
442	Bâ€…Embryogenesis of Ventricular Myocardial Trabeculae â€“ Novel Insights from Episcopic 3D Imaging and Fractal Analysis of Wild-type and Notch MIB1 Noncompaction Mouse Models. Heart, 2014, 100, A125-A128.	1.2	1
443	Response to Letter Regarding Article, â€œTreatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: An International Task Force Consensus Statementâ€. Circulation, 2016, 133, e437-8.	1.6	1
444	Novel strategies to evaluate the effectiveness of heart failure services. Revista Espanola De Cardiologia (English Ed), 2020, 73, 200-204.	0.4	1
445	Preventing Sudden Death in Arrhythmogenic Cardiomyopathy: Careful Family and Genetic Evaluation Key to Appropriate Diagnosis and Management. Canadian Journal of Cardiology, 2021, 37, 819-821.	0.8	1
446	Clinical Significance of Circulating Cardiac Autoantibodies in Dilated Cardiomyopathy and Myocarditis. Developments in Cardiovascular Medicine, 2003, , 97-109.	0.1	1
447	Diagnosis: Task Force Criteria including Modifications for Family Members. , 2007, , 87-96.		1
448	Diseases of the Myocardium and Endocardium. , 2012, , 318-333.		1
449	Reperfusion Arrhythmias are Rare during Acute Myocardial Infarction in Man. Clinical Science, 1988, 74, 2P-3P.	0.0	0
450	Systematic assessment of the factors influencing the efficacy of laser thermal angioplasty in the coronary circulation. , 1990, 1201, 162.		0

#	Article	IF	Citations
451	Genetics, pathophysiology, and prognosis of hypertrophic cardiomyopathy. Current Opinion in Cardiology, 1991, 6, 383-388.	0.8	0
452	Dilated cardiomyopathy: Pathogenesis and the recognition of early disease. Heart Failure Reviews, 1996, 1, 87-96.	1.7	0
453	Role of Invasive EP Testing in the Evaluation and Management of Hypertrophic Cardiomyopathies. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 86-88.	0.9	0
454	Genetic risk for acquired arrhythmia. Trends in Genetics, 2003, 19, 470-473.	2.9	0
455	Hypertrophic cardio-myopathy: In the family. Practice Nursing, 2005, 16, 484-487.	0.1	0
456	The Cardiomyopathies. , 0, , 109-131.		0
457	Arrhythmogenic Right Ventricular Cardiomyopathy in an Elite Black Athlete. Medicine and Science in Sports and Exercise, 2006, 38, S136.	0.2	0
458	MyBP-C phosphorylation in donor, failing and HOCM human heart muscle. Journal of Molecular and Cellular Cardiology, 2008, 44, 730-731.	0.9	0
459	The molecular phenotype of human cardiac myosin associated with hypertrophic obstructive cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2008, 44, 748-749.	0.9	0
460	What do tachycardiomyopathy belong to?: reply. European Heart Journal, 2008, 29, 1074-1074.	1.0	0
461	Is There a Role for the 12-Lead ECG in Pre-Participation Screening of Athletes?. Cardiology, 2008, 109, 144-144.	0.6	0
462	Arrhythmogenic Right Ventricular Cardiomyopathy. , 0, , 136-150.		0
463	Direct Evidence In Man For Haploinsufficiency As The Mechanism Of Action Of Myosin-binding Protein C Mutations That Cause Hypertrophic Cardiomyopathy. Biophysical Journal, 2009, 96, 371a.	0.2	0
464	061â€...Metabolic alteration in hypertrophic cardiomyopathy (METAL-HCM Study): randomised double blinded placebo controlled trial of perhexiline therapy in patient with hypertrophic cardiomyopathy. Heart, 2010, 96, A36.2-A36.	1.2	0
465	069â€...Cardiac myosin binding protein C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome. Heart, 2010, 96, A40.2-A40.	1.2	0
466	Response to Letter Regarding Article, â€œHigh-Density Substrate Mapping in Brugada Syndrome: Combined Role of Conduction and Repolarization Heterogeneities in Arrhythmogenesisâ€• Circulation, 2010, 121, .	1.6	0
467	Inherited Myocardial Diseases. , 2010, , 21-76.		0
468	Clinical Heterogeneity of Cardiomyopathies Due to Mutations in Myopalladin Gene. Journal of Cardiac Failure, 2010, 16, S1.	0.7	0

#	Article	IF	Citations
469	092â€…Interstitial expansion in health and diseaseâ€”an equilibrium contrast CMR study. Heart, 2012, 98, A53-A54.	1.2	0
470	073â€…Evaluation of clinical markers of early disease expression and the ability to predict genotype in families with HCM and mutations in cardiac myosin binding protein C. Heart, 2012, 98, A41.2-A42.	1.2	0
471	Manuel Penas Lado. Revista Espanola De Cardiologia (English Ed), 2012, 65, 388.	0.4	0
472	88â€…Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy. Heart, 2014, 100, A50.3-A51.	1.2	0
473	Functional Effects of the Î²-Myosin Mutation Arg453Cys in Familial Hypertrophic Cardiomyopathy. Biophysical Journal, 2014, 106, 771a.	0.2	0
474	Anomalous Left Coronary Artery in Hypertrophic Cardiomyopathy. Annals of Thoracic Surgery, 2014, 97, 2190-2193.	0.7	0
475	Response by Andrews et al to Letter Regarding Article, â€œElectrical and Structural Substrate of Arrhythmogenic Right Ventricular Cardiomyopathy Determined Using Noninvasive Electrocardiographic Imaging and Late Gadolinium Magnetic Resonance Imagingâ€. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	0
476	Misdiagnosis Of Hypertrophic Cardiomyopathy In An Elite Athlete. Medicine and Science in Sports and Exercise, 2005, 37, S131.	0.2	0
477	Clinical Outcomes and Current Therapies in Arrhythmogenic Right Ventricular Cardiomyopathy. , 2009, , 139-145.		0
478	Genetic Origins of Right Ventricular Cardiomyopathies. , 2009, , 119-124.		0
479	Risk Stratification in Patients with Hypertrophic Cardiomyopathy. Developments in Cardiovascular Medicine, 1998, , 83-88.	0.1	0
480	ç¬¬15å›žæ—¥æœ¬å¿ƒé›»å¦ä¼šå¦è¡“é›†ä¼š ä¸Šç”°èˆ¬é¨¨å¿µè¬›æ¼”æŠ„éŒ². Japanese Journal of Electrocardiology, 1998, 18, 574-	0.0	0